Aevum Zenth’s Biopharma Division bridges discovery, development, and commercialization. We partner with research institutions, biotech startups, and global pharmaceutical leaders to transform breakthrough science into life-changing therapies.
We provide end-to-end capabilities aligned with modern biopharma development pathways.
Target identification, hit-to-lead optimization, assay development, and computational biology powered by our Zenth Digital AI modeling platforms.
Phase I–IV trial design, patient recruitment networks, decentralized clinical trial infrastructure, and real-world evidence generation across 40+ regions.
GMP-compliant facilities for biologics, cell & gene therapies, and small molecules. Scale-up support, quality assurance, and global supply chain logistics.
Strategic submissions to FDA, EMA, PMDA, and NMPA. Health economics, pricing strategy, reimbursement pathways, and post-marketing surveillance.
Our multidivisional infrastructure eliminates traditional biopharma bottlenecks.
Flexible collaboration structures tailored to your stage and strategic goals.
Long-term co-development agreements sharing IP, resources, and commercial rights across specific therapeutic areas.
In-licensing of novel modalities (ADCs, mRNA, CRISPR) with milestone-based payments and exclusive territorial rights.
Access to Aevum Zenth’s trial sites, biomarker labs, and pharmacovigilance systems for accelerated program advancement.
Seed funding, mentorship, and facility access for biotech startups transitioning from academia to IND-enabling studies.
A structured, transparent pathway from initial inquiry to commercial launch.
Confidential intake, scientific feasibility review, and strategic fit assessment by our Cross-Discipline Evaluation Committee.
IP validation, regulatory pathway mapping, financial modeling, and term sheet negotiation with dedicated legal & commercial teams.
Joint steering committee formation, milestone tracking system setup, and cross-functional team onboarding.
Agile program management, real-time data sharing, and continuous risk mitigation through quarterly business reviews.
Global market launch support, post-approval monitoring, and next-generation indication expansion planning.
Our biopharma partnership team responds within 48 hours.
Whether you hold a novel platform, a pipeline asset, or specialized expertise, we structure partnerships that de-risk development and accelerate patient access.